MedTrace Logo

Ventricular Assist Device (VAD) Infection Prevention Survey

NCT03843021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 208

Last updated 2023-07-14

No results posted yet for this study

Summary

Annually, more than 250,000 patients in the U.S. with end-stage heart failure stand to benefit from ventricular assist device (VAD) therapy. 60% of patients develop a healthcare-associated infection (HAI) within 90-days of implantation. The investigators long term goal is to develop and subsequently promote wide-scale adoption of evidence-based HAI prevention practices following durable VAD implantation.

This will be done by addressing the following aims:

Aim 1. Identify determinants of center-level variability in HAI rates. Aim 2. Develop a comprehensive understanding of barriers and facilitators for achieving low center HAI rates.

Aim 3. Develop, iteratively enhance, and disseminate a best practices toolkit for preventing HAIs that accommodates various center contexts.

The investigators will use a focused survey of U.S. VAD centers to identify determinants of center variation in 90-day HAI rates:

* Process Factors (e.g., intranasal mupirocin),
* Provider Factors (e.g., surgeon technique),
* Device Factors (e.g., centrifugal vs. axial),
* Center Factors (e.g., provider communication).

Understanding the barriers and facilitators within individual centers for maximizing adoption of prevention measures would serve as the foundation for targeted improvement strategies. Without this knowledge, evidence-based, action-oriented recommendations will have limited local adoption and ultimately effectiveness in preventing HAIs after VAD implantation.

Conditions

  • Heart Failure
  • Healthcare Associated Infection
  • Ventricular Assist Device

Interventions

OTHER

VAD Infection Prevention Survey

Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.

Sponsors & Collaborators

Principal Investigators

  • Donald S Likosky, Ph.D. · University of Michigan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2022-12-23
Completion
2022-12-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843021 on ClinicalTrials.gov